Delhi high court refuses to stay Covaxin clinical trial on children aged 2-18

First batch of drug 2-DG expected to be launched next week for COVID patients

Serum Institute gets DCGI nod to resume trials of Oxford COVID-19 vaccine

<p>Drugs Controller General of India (DCGI) Dr V.G. Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trials. The DCGI, however, put certain conditions like taking […]</p>